Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481325 · ClinicalTrials.gov registry record · Phase 2
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder
A Phase 2 study of Generalized Anxiety Disorder, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT00481325: Completed Phase 2 study of Generalized Anxiety Disorder, sponsored by Bristol-Myers Squibb.
NCT00481325 is a Phase 2 study of Generalized Anxiety Disorder that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants, above the 209-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481325, a Phase 2 study of Generalized Anxiety Disorder, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
Conditions Studied
Interventions
- DRUG placebo
- DRUG escitalopram
- DRUG pexacerfont
Study Locations (20)
California
- Pacific Clinical Research Medical Group - Burbank
- Us Clinical Research Centers, Llc - Costa Mesa
- Pacific Institute For Medical Research, Inc. - Los Angeles
- Affiliated Research Institute - San Diego
- Pacific Clinical Research Medical Group - Upland
Florida
- Meridien Research - Brooksville
- Clinical Neuroscience Solutions - Jacksonville
- Comprehensive Neuroscience, Inc. - St. Petersburg
- Stedman Clinical Trials - Tampa
- Janus Center For Psychiatric Research - West Palm Beach
Connecticut
- University Of Connecticut Health Center - Farmington
- Comprehensive Psychiatric Care, Pc - Norwich
Indiana
- Indiana University School Of Medicine - Indianapolis
- Alpine Clinic - Lafayette
Kansas
- Cientifica, Inc. At Prairie View Inc. - Newton
- Ctt, Inc. - Prairie Village
Arizona
- Pivotal Research Centers - Mesa
Colorado
- Radiant Research, Inc. - Denver
Georgia
- Carman Research - Smyrna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00481325 record still lists
NCT00481325 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 209-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00481325 names 20 study sites across 9 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00481325 about?
NCT00481325 is a clinical study titled "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder". The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
What is the current status of trial NCT00481325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2007-07. Estimated completion is 2008-03.
What conditions does trial NCT00481325 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00481325?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG), pexacerfont (DRUG).
Who is sponsoring clinical trial NCT00481325?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00481325 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00481325's enrollment target sits among peer trials
260 13th of 48 higher than 36 of 48 other Generalized Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Use of CBD in the Treatment of Anxiety
RECRUITING · Phase 2
-
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
RECRUITING · Phase 2
-
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
ACTIVE NOT RECRUITING · Phase 2
-
Combined Treatment for Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia